These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28216328)

  • 1. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
    Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
    J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
    Bonde Miranda T; Garmo H; Stattin P; Robinson D
    J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
    Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
    Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
    Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
    Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
    Kearns JT; Faino AV; Schenk JM; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner A; Zheng Y; Lin DW
    J Urol; 2019 Jan; 201(1):106-111. PubMed ID: 30076904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy.
    Heo JE; Koo KC; Hong SJ; Park SU; Chung BH; Lee KS
    Yonsei Med J; 2018 Mar; 59(2):219-225. PubMed ID: 29436189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.
    Taussky D; Piotte J; Zorn KC; Zanaty M; Krishnan V; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Delouya G
    Strahlenther Onkol; 2018 Jan; 194(1):17-22. PubMed ID: 28695317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
    Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
    J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults.
    Kumar A; Nalawade V; Riviere P; Sarkar RR; Parsons JK; Murphy JD; Rose BS
    JAMA Netw Open; 2019 Oct; 2(10):e1913612. PubMed ID: 31626312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
    Murtola TJ; Peltomaa AI; Talala K; Määttänen L; Taari K; Tammela TLJ; Auvinen A
    Eur Urol Focus; 2017 Apr; 3(2-3):212-220. PubMed ID: 28753762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
    Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
    JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
    J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.
    Fradet V; Toren P; Nguile-Makao M; Lodde M; Lévesque J; Léger C; Caron A; Bergeron A; Ben-Zvi T; Lacombe L; Pouliot F; Tiguert R; Dujardin T; Fradet Y
    BJU Int; 2018 Mar; 121(3):399-404. PubMed ID: 28972698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
    Helfand BT; Blackwell RH; McVary KT
    J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
    Marks LS; Andriole GL; Fitzpatrick JM; Schulman CC; Roehrborn CG
    J Urol; 2006 Sep; 176(3):868-74. PubMed ID: 16890642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
    Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
    J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.